187 related articles for article (PubMed ID: 21115652)
1. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.
Yang SW; Cody JJ; Rivera AA; Waehler R; Wang M; Kimball KJ; Alvarez RA; Siegal GP; Douglas JT; Ponnazhagan S
Clin Cancer Res; 2011 Feb; 17(3):538-49. PubMed ID: 21115652
[TBL] [Abstract][Full Text] [Related]
2. Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.
Yang SW; Chanda D; Cody JJ; Rivera AA; Waehler R; Siegal GP; Douglas JT; Ponnazhagan S
PLoS One; 2011; 6(10):e25131. PubMed ID: 22022379
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
[TBL] [Abstract][Full Text] [Related]
6. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
7. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
8. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
9. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
10. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
11. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
12. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.
Zhu ZB; Rivera AA; Makhija SK; Lu B; Wang M; Izumi M; Cerfolio RJ; Stoff-Khalili MA; Zhou F; Takayama K; Siegal GP; Curiel DT
Lung Cancer; 2007 Feb; 55(2):145-56. PubMed ID: 17113184
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
14. Armed replicating adenoviruses for cancer virotherapy.
Cody JJ; Douglas JT
Cancer Gene Ther; 2009 Jun; 16(6):473-88. PubMed ID: 19197323
[TBL] [Abstract][Full Text] [Related]
15. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Raki M; Kanerva A; Ristimaki A; Desmond RA; Chen DT; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
Gene Ther; 2005 Aug; 12(15):1198-205. PubMed ID: 15800658
[TBL] [Abstract][Full Text] [Related]
16. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.
Cody JJ; Rivera AA; Lyons GR; Yang SW; Wang M; Sarver DB; Wang D; Selander KS; Kuo HC; Meleth S; Feng X; Siegal GP; Douglas JT
Cancer Gene Ther; 2010 Dec; 17(12):893-905. PubMed ID: 20798695
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
[TBL] [Abstract][Full Text] [Related]
18. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
19. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]